Last updated: 2026-09-16 10:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Achieve Life Sciences, Inc. (ACHV) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $7.26, with a market capitalisation of $743.99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.62 to $8.64. This page covers its latest market performance, valuation, price trends and company information.
$743.99M | |
$7.26 | |
$970.00 | |
$1.84 | |
$7.32 | |
305.00 | |
1.85M | |
-- | |
$8.64 | |
$2.62 | |
-- | |
-- |
Achieve Life Sciences, Inc. (ACHV) is trading at $7.26 in pre-market trading as of 2026-09-16 08:03:00, down 0.82% ($0.06) from the previous close of $7.32
Pre-market trading shows how investors are pricing ACHV before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Achieve Life Sciences, Inc. (ACHV) moved from $8.49 to $7.26, representing a decline of 14.49% ($1.23).
The stock traded between $7.01 and $8.56 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.93 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 77.1%
ACHV is currently trading at $7.26, placing it 77.1% of the way from its 52-week low of $2.62 to its 52-week high of $8.64. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Achieve Life Sciences, Inc. (ACHV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.